Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ernest U. Conrad

Showing results (51-60 of 63) with videos related to

Pageof 7
Sort By:
Cancer|December 14, 2004
Deep-seated, well differentiated lipomatous tumors of the chest wall and extremities: the role of cytogenetics in classification and prognosticationMikelle D Bassett, Scott M Schuetze, Christine Disteche, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 10, 2004
Hypoxia and glucose metabolism in malignant tumors: evaluation by [18F]fluoromisonidazole and [18F]fluorodeoxyglucose positron emission tomography imagingJoseph G Rajendran, David A Mankoff, Finbarr O'Sullivan, et al.
Journal of Orthopaedic Research : Official Publication of the Orthopaedic Research Society|June 9, 2004
Targeting of EWS/FLI-1 by RNA interference attenuates the tumor phenotype of Ewing's sarcoma cells in vitroHoward A Chansky, Fariba Barahmand-Pour, Qi Mei, et al.
Journal for Immunotherapy of Cancer|April 10, 2020
Histiocyte predominant myocarditis resulting from the addition of interferon gamma to cyclophosphamide-based lymphodepletion for adoptive cellular therapyBrett A Schroeder, Ralph Graeme Black, Sydney Spadinger, et al.
Plos One|March 3, 2012
NYESO-1/LAGE-1s and PRAME are targets for antigen specific T cells in chondrosarcoma following treatment with 5-Aza-2-deoxycitabineSeth M Pollack, Yonqing Li, Megan J Blaisdell, et al.
Cancer|February 24, 2012
NY-ESO-1 is a ubiquitous immunotherapeutic target antigen for patients with myxoid/round cell liposarcomaSeth M Pollack, Achim A Jungbluth, Benjamin L Hoch, et al.
Cancer|July 29, 2009
Addition of muramyl tripeptide to chemotherapy for patients with newly diagnosed metastatic osteosarcoma: a report from the Children's Oncology GroupAlexander J Chou, Eugenie S Kleinerman, Mark D Krailo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 1, 2005
TP53 mutations and outcome in osteosarcoma: a prospective, multicenter studyJay S Wunder, Nalan Gokgoz, Robert Parkes, et al.
Journal for Immunotherapy of Cancer|October 16, 2014
Tetramer guided, cell sorter assisted production of clinical grade autologous NY-ESO-1 specific CD8(+) T cellsSeth M Pollack, Robin L Jones, Erik A Farrar, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|April 11, 2014
Soft tissue sarcoma, version 2.2014Margaret von Mehren, R Lor Randall, Robert S Benjamin, et al.
Pageof 7

Showing results (51-60 of 63) with videos related to

Sort By:
Pageof 7
Cancer|December 14, 2004
Deep-seated, well differentiated lipomatous tumors of the chest wall and extremities: the role of cytogenetics in classification and prognosticationMikelle D Bassett, Scott M Schuetze, Christine Disteche, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 10, 2004
Hypoxia and glucose metabolism in malignant tumors: evaluation by [18F]fluoromisonidazole and [18F]fluorodeoxyglucose positron emission tomography imagingJoseph G Rajendran, David A Mankoff, Finbarr O'Sullivan, et al.
Journal of Orthopaedic Research : Official Publication of the Orthopaedic Research Society|June 9, 2004
Targeting of EWS/FLI-1 by RNA interference attenuates the tumor phenotype of Ewing's sarcoma cells in vitroHoward A Chansky, Fariba Barahmand-Pour, Qi Mei, et al.
Journal for Immunotherapy of Cancer|April 10, 2020
Histiocyte predominant myocarditis resulting from the addition of interferon gamma to cyclophosphamide-based lymphodepletion for adoptive cellular therapyBrett A Schroeder, Ralph Graeme Black, Sydney Spadinger, et al.
Plos One|March 3, 2012
NYESO-1/LAGE-1s and PRAME are targets for antigen specific T cells in chondrosarcoma following treatment with 5-Aza-2-deoxycitabineSeth M Pollack, Yonqing Li, Megan J Blaisdell, et al.
Cancer|February 24, 2012
NY-ESO-1 is a ubiquitous immunotherapeutic target antigen for patients with myxoid/round cell liposarcomaSeth M Pollack, Achim A Jungbluth, Benjamin L Hoch, et al.
Cancer|July 29, 2009
Addition of muramyl tripeptide to chemotherapy for patients with newly diagnosed metastatic osteosarcoma: a report from the Children's Oncology GroupAlexander J Chou, Eugenie S Kleinerman, Mark D Krailo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 1, 2005
TP53 mutations and outcome in osteosarcoma: a prospective, multicenter studyJay S Wunder, Nalan Gokgoz, Robert Parkes, et al.
Journal for Immunotherapy of Cancer|October 16, 2014
Tetramer guided, cell sorter assisted production of clinical grade autologous NY-ESO-1 specific CD8(+) T cellsSeth M Pollack, Robin L Jones, Erik A Farrar, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|April 11, 2014
Soft tissue sarcoma, version 2.2014Margaret von Mehren, R Lor Randall, Robert S Benjamin, et al.
Pageof 7